We have located links that may give you full text access.
Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHA 2 DS 2 -VASc score-a nationwide cohort study.
Oncotarget 2018 January 27
Purpose: The current study aimed to explore the impact of atrial fibrillation (AF) on risk of ischemic stroke among cancer patients classified by CHA2 DS2 -VASc score.
Methods: Study participants were identified from Registry for Catastrophic Illness Patient Database. All cancer patients whether they had comorbid AF or not were divided into 4 groups according to their CHA2 DS2 -VASc score-a score of 0-1, 2-3, 4-5 and >5. Competing risk analysis was used to evaluate the subhazard ratios (SHRs) and 95% confidence intervals (CIs) of incident ischemic stroke between cancer patients with and without AF according to their CHA2 DS2 -VASc score.
Results: A total of 781473 patients with cancer were identified. Of them, 21134 had comorbid AF whereas the remaining 760339 patients did not. After controlling for the confounding factors and the competing risk of death, among cancer patients, those with AF were associated with the highest risk of ischemic stroke than those without AF while their CHA2 DS2 -VASc score was 0∼1 (adjusted SHR [aSHR] = 4.15, 95% CI = 3.29-5.23). Among those with a CHA2 DS2 -VASc score of >5, the AF group exhibited a 1.82-fold higher risk of ischemic stroke than the non-AF group (95% CI = 1.34-2.47).
Conclusions: The impact of AF on risk of ischemic stroke was attenuated with advancing CHA2 DS2 -VASc score in patients with cancer.
Methods: Study participants were identified from Registry for Catastrophic Illness Patient Database. All cancer patients whether they had comorbid AF or not were divided into 4 groups according to their CHA2 DS2 -VASc score-a score of 0-1, 2-3, 4-5 and >5. Competing risk analysis was used to evaluate the subhazard ratios (SHRs) and 95% confidence intervals (CIs) of incident ischemic stroke between cancer patients with and without AF according to their CHA2 DS2 -VASc score.
Results: A total of 781473 patients with cancer were identified. Of them, 21134 had comorbid AF whereas the remaining 760339 patients did not. After controlling for the confounding factors and the competing risk of death, among cancer patients, those with AF were associated with the highest risk of ischemic stroke than those without AF while their CHA2 DS2 -VASc score was 0∼1 (adjusted SHR [aSHR] = 4.15, 95% CI = 3.29-5.23). Among those with a CHA2 DS2 -VASc score of >5, the AF group exhibited a 1.82-fold higher risk of ischemic stroke than the non-AF group (95% CI = 1.34-2.47).
Conclusions: The impact of AF on risk of ischemic stroke was attenuated with advancing CHA2 DS2 -VASc score in patients with cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app